CASCINU, Stefano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 17.888
EU - Europa 5.865
AS - Asia 1.780
AF - Africa 27
SA - Sud America 25
Continente sconosciuto - Info sul continente non disponibili 21
OC - Oceania 19
Totale 25.625
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 17.817
GB - Regno Unito 2.104
IT - Italia 1.033
CN - Cina 630
SE - Svezia 630
DE - Germania 567
HK - Hong Kong 467
IE - Irlanda 440
UA - Ucraina 392
TR - Turchia 321
FI - Finlandia 209
BG - Bulgaria 188
FR - Francia 145
VN - Vietnam 109
IN - India 86
CA - Canada 62
JP - Giappone 41
BE - Belgio 32
MY - Malesia 26
EG - Egitto 24
RU - Federazione Russa 23
IQ - Iraq 22
TW - Taiwan 22
NL - Olanda 19
EU - Europa 17
RO - Romania 15
AU - Australia 14
ES - Italia 12
KR - Corea 12
SG - Singapore 11
BR - Brasile 10
CH - Svizzera 10
IR - Iran 8
NO - Norvegia 8
CL - Cile 7
ID - Indonesia 7
MX - Messico 6
MT - Malta 5
NZ - Nuova Zelanda 5
PK - Pakistan 5
PT - Portogallo 5
A2 - ???statistics.table.value.countryCode.A2??? 4
AT - Austria 4
LU - Lussemburgo 4
PH - Filippine 4
BZ - Belize 3
CZ - Repubblica Ceca 3
EC - Ecuador 3
IS - Islanda 3
PL - Polonia 3
BD - Bangladesh 2
IL - Israele 2
KZ - Kazakistan 2
MD - Moldavia 2
MK - Macedonia 2
PE - Perù 2
SI - Slovenia 2
VE - Venezuela 2
AE - Emirati Arabi Uniti 1
AR - Argentina 1
BN - Brunei Darussalam 1
DK - Danimarca 1
ET - Etiopia 1
GR - Grecia 1
HR - Croazia 1
LV - Lettonia 1
MA - Marocco 1
OM - Oman 1
SK - Slovacchia (Repubblica Slovacca) 1
ZM - Zambia 1
Totale 25.625
Salva come PNG Salva come JPEG
Città #
Fairfield 3.266
Woodbridge 1.822
Southend 1.684
Ashburn 1.492
Houston 1.438
Seattle 1.283
Chandler 1.210
Cambridge 1.033
Wilmington 1.011
Jacksonville 744
Dearborn 740
Ann Arbor 738
Nyköping 475
Hong Kong 464
Dublin 436
Modena 305
Beijing 271
San Diego 245
Izmir 219
Princeton 190
Sofia 188
Eugene 175
New York 122
Dong Ket 105
Helsinki 98
Falls Church 91
London 88
Bremen 64
Fremont 61
Boardman 58
Milan 57
Redwood City 57
Ottawa 45
Shanghai 40
San Giuliano Milanese 37
Phoenix 32
Norwalk 29
Brussels 28
Hefei 26
Rome 25
Asyut 21
Baghdad 21
Bologna 20
Kilburn 20
Chiswick 19
Nanjing 18
Tokyo 17
Kunming 16
Banqiao 14
Florence 14
Guangzhou 14
Jinan 14
Siena 14
Absecon 13
Napoli 13
Des Moines 12
Hounslow 12
Paris 12
Los Angeles 11
San Mateo 11
Detroit 9
Indiana 9
Toronto 9
Augusta 8
Fuzhou 8
Grafing 8
Mountain View 8
Mumbai 8
Shenyang 8
Chengdu 7
Prescot 7
Xian 7
Carpi 6
Chicago 6
Edinburgh 6
Gunzenhausen 6
Nanchang 6
Parma 6
Piacenza 6
San Jose 6
San Marco 6
Sassuolo 6
Tappahannock 6
Verona 6
Acri 5
Angera 5
Bangalore 5
Brooklyn 5
Changchun 5
Dresden 5
Falkenstein 5
Garbagnate Milanese 5
Groningen 5
Hangzhou 5
Hyderabad 5
Longiano 5
Lugano 5
Mykolayiv 5
Oslo 5
Pune 5
Totale 21.046
Salva come PNG Salva come JPEG
Nome #
Cancer Treatment Induced Bone Loss (CTIBL) in breast cancer women: a multidisciplinary approach at the Modena Cancer Center screening over 600 patients. 357
GD2 expression in breast cancer. 280
Impact of time to surgery after neoadjuvant chemotherapy in operable breast cancer patients 260
Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going 242
Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer 242
Endocrine sensitive metastatic breast cancer and bone only disease: are the new treatments always better? 237
BRAF ,NRASandC-KITAdvanced Melanoma: Clinico-pathological Features, Targeted-Therapy Strategies and Survival 229
Transient sunitinib resistance in gastrointestinal stromal tumors. 220
Differential molecular pathways expression in HER2 positive early breast cancer according to hormone receptor status. 212
Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus 211
A Dose-finding and Biomarker Evaluation Phase Ib Study of Everolimus in Association With 5-Fluorouracil and Pelvic Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Cancer (E-LARC Study) 202
M09Quantification of circulating cell-free DNA by fluorimetry (Qubit) and spectrophotometry (NanoDrop) in patients with malignant melanoma and prostate cancer 201
Atrial fibrillation in patients with active malignancy and use of anticoagulants: Under-prescription but no adverse impact on all-cause mortality 197
Post-surgical pyoderma gangrenosum of the breast: needs for early diagnosis and right therapy. 194
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? 193
Hereditary pancreatic cancer: A retrospective single-center study of 5143 Italian families with history of BRCA-related malignancies 193
Metronomic Capecitabine Effectively Blocks Leptomeningeal Carcinomatosis From Breast Cancer: A Case Report and Literature Review. 189
Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients 188
Angiogenesis in pancreatic ductal adenocarcinoma: A controversial issue 186
Quality of life and anxious-depressive symptoms in cancer patients undergoing mindfulness-based interventions: Feasibility and preliminary outcomes on prospective single-centre case-control study (MIND4ME St.) 186
Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients. 186
Randomized trial of low-dose morphine versus weak opioids in moderate cancer pain 186
Tumor VEGF expression correlates with tumor stage and identifies prognostically different groups in patients with clear cell renal cell carcinoma 185
Predictive role of haemoglobin on disease response to neoadjuvant chemotherapy in breast cancer. 184
Osteonecrosis of the Jaw in a Breast Cancer Patient Treated with Everolimus and a Single Dose of Zoledronic Acid. 181
First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: Final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial 180
Combined Hormonal Contraceptive Use and Risk of Breast Cancer in a Population of Women With a Family History 180
5-Fluorouracil pharmacogenomics: still rocking after all these years? 178
Gastrointestinal neuroendocrine tumors: Searching the optimal treatment strategy-A literature review 177
Impact of body composition parameters on tumor response to neoadjuvant chemotherapy in operable breast cancer patients. 176
Clinical and molecular analysis of long-term HER2 positive metastatic breast cancer survivors. 175
Are post-docetaxel treatments effective in patients with castration-resistant prostate cancer and performance of 2? A meta-analysis of published trials. 174
Il trattamento di prima e seconda linea nel carcinoma gastrico 171
VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study 170
Androgen receptor expression in early triple-negative breast cancer: clinical significance and prognostic associations. 170
The evolving role of microsatellite instability in colorectal cancer: A review 169
ERBB2 mutations in hormone receptor positive primary breast cancers samples and in their matched endocrine-resistant recurrences. 169
The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer 168
Profile of lenvatinib in the treatment of hepatocellular carcinoma: design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all Phase III trials 167
Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat? 166
[11C]-Methionine Positron Emission Tomography in the Postoperative Imaging and Followup of Patients with Primary and Recurrent Gliomas 165
A novel approach to manage skin toxicity caused by therapeutic agents targeting epidermal growth factor receptor. 165
Role of evaluating tumor‑infiltrating lymphocytes, programmed death‑1 ligand 1 and mismatch repair proteins expression in malignant mesothelioma 162
Safety and efficacy of T-DM1 in HER2 positive metastatic breast cancer patients: a real word experience. 161
Multimodal treatment of resectable pancreatic ductal adenocarcinoma 161
Reply to O. Corli et al and M. Lucchesi et al 160
Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New 160
Cancer stem cell gene profile as predictor of relapse in high risk stage II and stage III, radically resected colon cancer patients. 159
Prognostic models to predict survival in patients with advanced non-small cell lung cancer treated with first-line chemo- or targeted therapy 159
Adjuvant chemotherapy in colon cancer: can we improve quality of care? 158
A randomized, double blind, placebo-controlled study to assess QTc interval prolongation of standard dose aflibercept in cancer patients treated with docetaxel. 157
Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma. 157
Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier) 156
Quantification of circulating cell-free DNA by fluorimetry (Qubit) and spectrophotometry (NanoDrop) in patients with malignant melanoma and prostate cancer 155
Differential gene expression patterns in HER2 positive metastatic breast cancer patients according to hormone receptor status 154
Selecting the best treatment for an individual patient. 153
Tumor Angiogenesis: A Target for Renal Cell Carcinoma Therapy.Current Perspectives and Novel Strategies 153
Allele polymorphisms of tumor integrins correlate with peritoneal carcinosis capability of gastric cancer cells in radically resected patients. 153
The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab. 152
Role of vascular endothelial growth factor (VEGF) and VEGF-R genotyping in guiding the metastatic process in pT4a resected gastric cancer patients. 152
ANGPT2 and NOS3 Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib 152
The Italian Rare Pancreatic Exocrine Cancer Initiative 152
Protracted low doses of temozolomide for the treatment of patients with recurrent glioblastoma: A phase II study. 151
Thymic neoplasms: an update on the use of chemotherapy and new targeted therapies. A literature review. 151
Clinical evidence for three distinct gastric cancer subtypes: time for a new approach. 151
Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab. 151
Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale 151
Role of natural and adaptive immunity in renal cell carcinoma response to VEGFR-TKIs and mTOR inhibitor. 150
Progress of molecular targeted therapies for advanced renal cell carcinoma. 149
The role of LDH serum levels in predicting global outcome in HCC patients undergoing TACE: implications for clinical management. 149
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. 149
Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients. 149
Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol 149
Correlation of Stomatitis and Cutaneous Toxicity With Clinical Outcome in Patients With Metastatic Renal-Cell Carcinoma Treated With Everolimus 147
Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib 147
Sub-cellular localization analysis of MSH6 missense mutations does not reveal an overt MSH6 nuclear transport impairment. 146
Gastro-entero-pancreatic neuroendocrine tumors: Is now time for a new approach? 146
Phase II study of pharmacogenetic-tailored therapy in elderly colorectal cancer patients. 145
State of the art for cardiotoxicity due to chemotherapy and to targeted therapies: a literature review. 145
The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management 145
Molecular profile in primary and metastatic breast cancer treated with Exemestane and Everolimus. 144
Primary and secondary prevention to effectively reduce the risk of bisphosphonate-related osteonecrosis of the jaw in patients with bone metastases . 144
The prognostic role of hemoglobin levels in patients undergoing concurrent chemo-radiation for anal cancer 144
First-Line Treatment for Endocrine-Sensitive Bone-Only Metastatic Breast Cancer: Systematic Review and Meta-analysis 144
Efficacy and safety of second-line fotemustine in elderly patients with recurrent glioblastoma 143
FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study. 143
Molecular biomarkers of resistance to anti-EGFR treatment in metastatic colorectal cancer, from classical to innovation. 143
Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study. 143
Role of SIRT-3, p-mTOR and HIF-1α in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin 143
Neutrophil-to-lymphocyte ratio may be associated with the outcome in patients with prostate cancer 142
Pegylated liposomal doxorubicin, 5-fluorouracil and cisplatin versus mitomycin-C, 5-fluorouracil and cisplatin for advanced gastric cancer: a randomized phase II trial. 142
Tumor angiogenesis genotyping and efficacy of first-line chemotherapy in metastatic gastric cancer patients. 141
Nuclear factor-κB predicts outcome in locally advanced rectal cancer patients receiving neoadjuvant radio-chemotherapy. 141
eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: Final results of the ePHAS study 141
Novel small molecule EGFR inhibitors as candidate drugs in non-small cell lung cancer. 140
Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: A retrospective study 140
Predictive Role Of Body Composition Parameters In Operable Breast Cancer Patients Treated With Neoadjuvant Chemotherapy. 140
Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: A systematic review and meta-analysis of clinical trials 139
Endocrine therapy alone versus targeted combination strategy as first line treatment in elderly patients with hormone receptor-positive advanced breast cancer: Meta-analysis of phase II and III randomized clinical trial 138
Class 1, 2, and 3 BRAF-mutated metastatic colorectal cancer: A detailed clinical, pathologic, and molecular characterization 138
Totale 16.891
Salva come PNG Salva come JPEG
Categoria #
all - tutte 96.241
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 96.241
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20191.925 0 0 0 0 0 0 0 0 0 0 919 1.006
2019/20206.382 583 241 144 409 657 1.124 1.070 711 697 272 346 128
2020/20215.431 547 204 448 437 609 469 420 649 308 569 377 394
2021/20223.594 237 432 328 153 100 253 186 193 384 354 657 317
2022/20233.617 422 366 229 322 412 425 54 284 787 44 151 121
2023/20241.760 77 118 117 195 425 121 258 351 43 54 1 0
Totale 25.972